Sign in
4

Changes in Ownership

Mineralys Therapeutics, Inc. Filed Acc 0001933414-23-000021

Options or other derivatives

  • Chief Executive Officer acquired 99,800 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Derivatives
Congleton Jon Chief Executive Officer 2023-03-17 Grant or award · Stock Option +99,800 99,800 D
Loading xslF345X04/wf-form4_167943887821849.xml…